alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# C_2009019EN.01001001.xml

| 24.1.2009 | EN | Official Journal of the European Union | C 19/10 |
| --- | --- | --- | --- |

24.1.2009

EN

Official Journal of the European Union

C 19/10

---

Judgment of the Court (Seventh Chamber) of 4 December 2008 — Commission of the European Communities v Grand Duchy of Luxembourg

(Case C-223/08) (1)

1

(Failure of a Member State to fulfil obligations - Directive 2006/100/EC - Non-transposition within the period prescribed)

(2009/C 19/16)

Language of the case: French

Parties

Applicant: Commission of the European Communities (represented by: C. Huvelin, acting as Agent)

Applicant:

Defendant: Grand Duchy of Luxembourg (represented by: C. Schiltz, Agent)

Defendant:

Re:

Failure of a Member State to fulfil its obligations — Failure to adopt or notify, within the prescribed period, the measures necessary to comply with Council Directive 2006/100/EC of 20 November 2006 adapting certain Directives in the field of freedom of movement of persons, by reason of the accession of Bulgaria and Romania (OJ 2006 L 363, p. 141)

Operative part of the judgment

The Court:

| 1. | Declares that, by failing to adopt, within the period prescribed, the laws, regulations and administrative provisions necessary to comply with Council Directive 2006/100/EC of 20 November 2006 adapting certain Directives in the field of freedom of movement of persons, by reason of the accession of Bulgaria and Romania, the Grand Duchy of Luxembourg has failed to fulfil its obligations under that directive; |
| --- | --- |

1.

Declares that, by failing to adopt, within the period prescribed, the laws, regulations and administrative provisions necessary to comply with Council Directive 2006/100/EC of 20 November 2006 adapting certain Directives in the field of freedom of movement of persons, by reason of the accession of Bulgaria and Romania, the Grand Duchy of Luxembourg has failed to fulfil its obligations under that directive;

| 2. | Orders the Grand Duchy of Luxembourg to pay the costs. |
| --- | --- |

2.

Orders the Grand Duchy of Luxembourg to pay the costs.

---

(1)  OJ C 171, 5.7.2008.

1

---
As a Lab - Entering results on a VS 10-11 Coggins form in VSPS

When you get an electronic lab submission log into VSPS, then click on Labs on the left.

Click on Find Test Records
The screen below shows the search screen where you can search for the submission.

You can search by any of the fields, but most commonly labs search using the Test Record # and click on Search. 

(The Test Record # is the Serial Number listed on the VS 10-11 form.)

The record will come up listed below the search criteria area. Click on Edit.

Enter the Received Date and Accession #.

Click on ‘Receive in Lab’.
If you don’t have any remarks you can enter the Test Results and Test Type Used.

If you need to enter remarks you can click on ‘Edit Specimen’ and enter the test results, test type used, and Remarks.

The Testing Complete Date will fill in as today’s date when you click ‘Mark Complete’. If you want it to be a different 

date you can enter the Date Complete in the Edit Specimen area.
1. View the VS 10-11 form and check for accuracy. 

2. If the form is accurate click on Mark Complete and the Vet will be able to view and print an Official Copy.

Please keep in mind no changes can be made to the form after you click on Mark Complete. The form will be Official at 

that time. In order to VOID the official form the AD at the Federal Office in your State will need to be contacted to 

receive approval to Void the form.

When you view the VS10-11 before you click Mark Complete and notice a change needs to be made, you can VOID the 

Unofficial form without approval from the AD. The vet can then resubmit the form with the corrections for you to enter 

the results on.
EXHIBIT 23.1


                     CONSENT OF CERTIFIED PUBLIC ACCOUNTANTS


 The Board of Directors
 American Healthchoice, Inc.

      We hereby consent to the incorporation by reference of our report dated
 November, 2001,  into the following registration statements filed  by you on
 Form S-8:  File No. 333-36475  dated September 29, 1997;  File No. 333-35581
 dated September 18, 1997;  File No. 333-26061 dated April 30, 1997; File No.
 333-26065 dated April 30, 1997; File No. 333-26043 dated April 30, 1997; and
 File No. 333-26063 dated April 30, 1997.


 Lane Gorman Trubitt, L.L.P.
 Dallas, Texas
 December 29, 2003
17130

#### Morley v. Spring

March 12, 1997

Order No. 97-24

Affirmed
# C_2019054EN.01000402.xml

| 11.2.2019 | EN | Official Journal of the European Union | C 54/4 |
| --- | --- | --- | --- |

11.2.2019

EN

Official Journal of the European Union

C 54/4

---

Request for a preliminary ruling from the Tribunalul Specializat Mureș (Romania) lodged on 7 November 2018 — SC Raiffeisen Bank SA v JB

(Case C-698/18)

(2019/C 54/06)

Language of the case: Romanian

Referring court

Tribunalul Specializat Mureș

Parties to the main proceedings

Applicant: SC Raiffeisen Bank SA

Defendant: JB

Questions referred

| 1. | Do the provisions of Council Directive 93/13/EEC on unfair terms in consumer contracts, (1) in particular the 12th, 21st and 23rd recitals and Articles 2(b), 6(1), 7(2) and 8 thereof, permit, in accordance with the principle of procedural autonomy and the principle of equivalence and effectiveness, a set of means of legal recourse that consists in an ordinary legal action, not subject to any limitation period, to establish the unfairness of certain terms in a consumer contract and an ordinary legal action of a personal and pecuniary nature that is subject to a limitation period, which is used in pursuit of the directive’s aim of eliminating the effects of all obligations arising and performed under clauses which are found to be unfair to consumers? |
| --- | --- |

1.

Do the provisions of Council Directive 93/13/EEC on unfair terms in consumer contracts, (1) in particular the 12th, 21st and 23rd recitals and Articles 2(b), 6(1), 7(2) and 8 thereof, permit, in accordance with the principle of procedural autonomy and the principle of equivalence and effectiveness, a set of means of legal recourse that consists in an ordinary legal action, not subject to any limitation period, to establish the unfairness of certain terms in a consumer contract and an ordinary legal action of a personal and pecuniary nature that is subject to a limitation period, which is used in pursuit of the directive’s aim of eliminating the effects of all obligations arising and performed under clauses which are found to be unfair to consumers?

| 2. | In the event that the first question is answered in the affirmative, do those same provisions preclude an interpretation, derived from application of the principle of the certainty of civil-law legal relationships, according to which the objective point in time by which the consumer must have known or should have known of the existence of the unfair terms is the time at which the loan agreement with that consumer came to an end? |
| --- | --- |

2.

In the event that the first question is answered in the affirmative, do those same provisions preclude an interpretation, derived from application of the principle of the certainty of civil-law legal relationships, according to which the objective point in time by which the consumer must have known or should have known of the existence of the unfair terms is the time at which the loan agreement with that consumer came to an end?

---

(1)  Council Directive 93/13/EEC of 5 April 1993 on unfair terms in consumer contracts (OJ 1993 L 95, p. 29).

---
Processing CVB Reference and Reagent Test Reports

ICWI3001.04 Page 1 of 2

Issuing Authority: Jeanette M. Watson

Issue Date: 14Jan15

Source Document and Date of Issuance or Edition: CVBSOP3001, Reference and Reagent Review and Release

1. Documents to be received at CVB-IC

CVBFRM0008 (FRM0008), CVB Reference and Reagent Test Report:

 One copy with Blocks 1-15 completed with original signature

 One copy of the Reagent Data Sheet

 One copy (if applicable) of the Production Protocol used to prepare the reference or 

reagent

2. CVB Processing 

 The packet is received by the Lead BCA.

 The Lead BCA stamps the date received at IC on the Form 0008 in Block 11,

CVBFRM0009 (Form 0009), Reagent Production Sign-Off Form, and the Reagent Data 

Sheet in the bottom right hand corner. 

 The Lead BCA routes the documents to the assigned Biologics Specialist.

3. Specialist Review 

 The Assigned Specialist reviews the Form 0008, Form 0009, and the Reagent Data Sheet 

and compares them with the Production Protocol for the product. The Production 

Protocol is available on the QM SharePoint Site.

 If the submitted Form 0008 and the Reagent Data Sheet are acceptable, the assigned 

Specialist checks “Test Completed Satisfactory” disposition in Block 16 of the Form 

0008 and signs their name in Block 17. The Specialist also signs the Form 0009. The 

Specialist initials the CVB-IC copy of the Reagent Data Sheet and the Production 

Protocol, if applicable, next to the date stamp.

 If the submitted Form 0008 and/or Reagent Data Sheet are not acceptable, the assigned 

Specialist contacts the PEL Section Agent/Test Contact for resolution and/or 

resubmission.

All approved documents are returned to the Lead BCA for processing

4. Final Processing 

 The Lead BCA reviews Block 16 of Form 0008 for disposition. (If a disposition is not 

checked, the Lead BCA returns the documents to the Specialist.) Blocks 18 and 19 (title 

and date) are stamped with the date the Lead BCA processes the paper. When processing 

is complete, the Lead BCA initials the Form 0008 on the top right hand corner and 

returns the Reference Reagent Folder to the QM Program Assistant.
Processing CVB Reference and Reagent Test Reports 

ICWI3001.04 Page 2 of 2

Issuing Authority: Jeanette M. Watson 

Issue Date: 14Jan15 

Source Document and Date of Issuance or Edition: CVBSOP3001, Reference and Reagent Review and Release 

 The Reagent Data Sheet and FRM0008 are scanned by the QM Program Assistant and 

uploaded to the CVB QMS SharePoint site, “Released Reagents”

. The Reference/Reagent Folder is returned to 

the originating Section by the QM Program Assistant unless otherwise instructed by the 

assigned Specialist.
NO. 07-06-0482-CR IN THE COUR

T OF APPEALS FOR THE SEVEN TH DISTRICT OF TEXAS

AT AMARILLO PANEL A JANUARY

30, 2007

______________________________ MIRIAM JENNETTE GRANADOS, APPELL ANT V. THE STATE OF TEXAS, A PPELLEE

_________________________________ FROM THE 2 42ND DIST RICT COURT OF HALE COU NTY; NO. B16346-0515; H ONORABLE ED SELF, JUDGE

_______________________________ Before CAMPBELL and HANCOCK and PIRTLE, JJ. ABA TEMENT AND REMAND Fo llowing an open p lea of guilty , Appellant Mi riam Jennette Gr anados was convicted of drivin g whil e intoxic ated. Electing to have the j ury asses s punishment, Appel lant was1 The due date f or the report er’s recor d is suspended by

this abatement. The reporter’srecord w ill be due thi rty day s after reinst atement. 2 sentenced to 180 days confinemen t and a $2,000 fin e. The clerk ’s rec ord was fil ed on January 22, 2007, and the repor ter’s reco rd has yet to be filed. 1 The trial court’s Ce rti fic at io n o f De fe nd an t’s Right of Appeal contained in the clerk’s record reflects “thedefendantwaiv ed the right of appeal.” After a careful examin ation of the clerk’s record, this

Court determi ned there is no w ritten waiver by Appellant of the r ight of appeal. An inquiry by

the appellate court clerk to the trial court cler k confirmed that no written waiver exis ts . We now abate the appeal and re mand the cause for an amended certification
. Upon remand, the tri al court shal l execute an ame nded certification correctly reflecting whether App e llant has t he right of appeal
. See generally Dears v. Sta te , 154 S.W.3d 610, 614 (Tex.C rim.App. 2005) ( concluding that an appellate court has the ability to examine a cer

tification for defecti veness and obt ain a no ther when app ropriate). The amended certification is to be included in a supp lemental clerk’s record to be filed wit h the clerk of thisCourt on or before March 2, 2 007. It is so or

dered. Per Curiam Do not publish
.
19331

#### State v. Galo

Affirmed
<TABLE>
<CAPTION>
                                  EXHIBIT 11.1
                              EASTON BANCORP, INC.
                        COMPUTATION OF EARNINGS PER SHARE
                           QUARTER ENDED JUNE 30, 1999



                                                        Three Months     Six Months
                                                           Ended           Ended
                                                       June 30, 1999   June 30, 1999
                                                       --------------  --------------
<S>                                                    <C>             <C>
Net income                                             $       69,568  $      113,996
                                                       ==============  ==============


Average shares outstanding                                    560,318         560,318
Basic earnings per share                               $         0.12  $         0.20
                                                       ==============  ==============


Average shares outstanding                                    560,318         560,318
Dilutive average shares outstanding under
 warrants and options                                         207,800         207,800
Exercise price                                         $        10.00  $        10.00
Assumed proceeds on exercise                           $    2,078,000  $    2,078,000
Average market value                                   $        12.25  $        12.25
Less:  Treasury stock purchased with assumed
       proceeds from exercise of warrants and options          169,633         169,633
Adjusted average shares-diluted                               598,485         598,485
Diluted earnings per share                             $         0.12  $         0.19
                                                       ==============  ==============
</TABLE>


     The stock of the Company is not traded on any public exchange.  The average
market  values  are  derived from trades known to management.  Private sales may
occur  where  management  of  the  Company  is  unaware  of  the  sales  price.

<PAGE>
<PAGE>


                                                                      EXHIBIT 32


                  FAIRFIELD INN BY MARRIOTT LIMITED PARTNERSHIP
                           FORM 10-K DECEMBER 31, 2003


                            CERTIFICATION PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

            In connection with the Annual Report of Fairfield Inn by Marriott
Limited Partnership, (the "Partnership"), on Form 10-K for the annual period
ended December 31, 2003, as filed with the Securities and Exchange Commission on
the date hereof (the "Report"), the undersigned, in the capacities and on the
date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: (1) the
Report fully complies with the requirements of Section 13(a) or 15(d) of the
Securities and Exchange Act of 1934; and (2) the information contained in the
Report fairly presents, in all material respects, the financial condition and
results of operations of the Partnership.


Date:  March 30, 2004                       /s/ Michael L. Ashner
                                            ---------------------
                                            Michael L. Ashner
                                            Chief Executive Officer


Date:  March 30, 2004                       /s/ Thomas C. Staples
                                            ---------------------
                                            Thomas C. Staples
                                            Chief Financial Officer
H. Res. 933 

In the House of Representatives, U. S., 

December 1, 2016. 

Resolved, 

SECTION 1. AMOUNTS FOR COMMITTEE EXPENSES. 

For further expenses of the Committee on Energy and 

Commerce (hereafter in this resolution referred to as the 

‘‘Committee’’) for the One Hundred Fourteenth Congress, 

there shall be paid out of the applicable accounts of the 

House of Representatives not more than $800,000. 

SEC. 2. VOUCHERS. 

Payments under this resolution shall be made on vouchers authorized by the Committee, signed by the Chairman of 

the Committee, and approved in the manner directed by the 

Committee on House Administration. 
2 

•HRES 933 EH 

SEC. 3. REGULATIONS. 

Amounts made available under this resolution shall be 

expended in accordance with regulations prescribed by the 

Committee on House Administration. 

Attest: 

Clerk.
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 9
<LEGEND>
This schedule contains summary financial information extracted from June 30,
1997 10QSB Financial Statements and is qualified in its entirety by reference to
such financial statements.
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               JUN-30-1997
<CASH>                                      12,296,264
<INT-BEARING-DEPOSITS>                               0
<FED-FUNDS-SOLD>                             1,090,000
<TRADING-ASSETS>                                     0
<INVESTMENTS-HELD-FOR-SALE>                 50,741,489
<INVESTMENTS-CARRYING>                       3,702,216
<INVESTMENTS-MARKET>                         3,716,743
<LOANS>                                    155,365,189
<ALLOWANCE>                                  1,845,103
<TOTAL-ASSETS>                             235,147,942
<DEPOSITS>                                 208,930,220
<SHORT-TERM>                                 7,224,547
<LIABILITIES-OTHER>                          1,492,666
<LONG-TERM>                                    160,002
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                     4,627,104
<OTHER-SE>                                  12,713,403
<TOTAL-LIABILITIES-AND-EQUITY>              17,340,507
<INTEREST-LOAN>                              6,960,750
<INTEREST-INVEST>                            1,897,726
<INTEREST-OTHER>                               121,626
<INTEREST-TOTAL>                             8,980,102
<INTEREST-DEPOSIT>                           4,026,427
<INTEREST-EXPENSE>                           4,130,230
<INTEREST-INCOME-NET>                        4,849,872
<LOAN-LOSSES>                                  464,012
<SECURITIES-GAINS>                             (18,340)
<EXPENSE-OTHER>                              4,154,940
<INCOME-PRETAX>                              1,355,627
<INCOME-PRE-EXTRAORDINARY>                   1,355,627
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 1,023,139
<EPS-PRIMARY>                                     0.66
<EPS-DILUTED>                                     0.66
<YIELD-ACTUAL>                                       0
<LOANS-NON>                                  1,450,983
<LOANS-PAST>                                    50,042
<LOANS-TROUBLED>                             1,081,487
<LOANS-PROBLEM>                                      0
<ALLOWANCE-OPEN>                             1,467,702
<CHARGE-OFFS>                                  134,410
<RECOVERIES>                                    47,798
<ALLOWANCE-CLOSE>                            1,845,102
<ALLOWANCE-DOMESTIC>                         1,845,102
<ALLOWANCE-FOREIGN>                                  0
<ALLOWANCE-UNALLOCATED>                              0
        

</TABLE>
EXHIBIT 32.1

                                 CERTIFICATIONS

  PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE
                           SARBANES-OXLEY ACT OF 2002




I, Michael W. Katz, certify that:

(1)  I have reviewed this quarterly report on Form 10-Q of E Com Ventures, Inc.;

(2)  Based on my knowledge,  this  quarterly  report does not contain any untrue
     statement of a material fact or omit to state a material fact  necessary to
     make the statements  made, in light of the  circumstances  under which such
     statements  were made, not misleading with respect to the period covered by
     this quarterly report; and

(3)  Based on my  knowledge,  the  financial  statements,  and  other  financial
     information  included  in this  quarterly  report,  fairly  present  in all
     material respects the financial  condition,  results of operations and cash
     flows of the  registrant  as of, and for,  the  periods  presented  in this
     quarterly report.



Date:  September 10, 2004



/s/ Michael W. Katz
--------------------------------------
Michael W. Katz
Chief Executive Officer and President
#### Ikeda v. Ikeda

19646

1/30/98

Affirmed
An Equal Opportunity Provider and Employer

CENTER FOR VETERINARY BIOLOGICS NOTICE NO. 17-02

TO: Veterinary Services Leadership Team 

Directors, Center for Veterinary Biologics 

Biologics Licensees, Permittees, and Applicants

FROM: Byron E. Rippke

Director

SUBJECT: Issuance of a Conditional License for Moraxella Bovoculi Bacterin

The Animal and Plant Health Inspection Service (APHIS) has issued a conditional 

United States Veterinary Biological Product License to Addison Biological 

Laboratory, Inc., Establishment No. 355, Fayette, Missouri, for the manufacture and 

distribution of Moraxella Bovoculi Bacterin.

A veterinary biological product regulated under the Virus-Serum-Toxin Act must be 

shown to be pure, safe, potent, and efficacious before a veterinary biological product 

license may be issued. The regulations in title 9, Code of Federal Regulations, part 

102, regarding the licensing of veterinary biological products provide that a 

conditional veterinary biological product license may be issued to meet an emergency

condition, limited market, local situation, or special circumstance. The special 

circumstance addressed here is the first availability of a Moraxella bovoculi vaccine 

against pinkeye or infectious bovine keratoconjunctivitis approved for use in cattle.

Conditionally licensed products are required to be pure and safe, and have a 

reasonable expectation of efficacy. This conditional license was issued on the basis 

that the licensee has demonstrated that the product has a reasonable expectation of 

efficacy. Safety of the product has been established through a safety study. APHIS 

will evaluate their progress throughout the next year. The conditional license will 

expire 1 year from the date of the license.

Animal and Plant

Health Inspection

Service

Veterinary Services

Center for Veterinary 

Biologics

1920 Dayton Avenue

PO Box 844

Ames, IA 50010

(515) 337-6100
19533

#### Peters v. Ivey

Affirmed
### D ISTRICT 

### C OURT 

### O F 

### A PPEAL 

### O F 

### T HE 

### S TATE 

### O F 

### F LORIDA

F OURTH D ISTRICT July Term 2014

C.C

- R., the mother

, Appellant,

v.

DEPARTMENT OF CHILDREN & FAMILIES
,

Appellee

.

No. 4D 14

- 403

[ July 16, 2014 ]

A ppeal from the Circuit Court for the Nineteenth Judicial Circuit, St. Lucie County ; Larry Schack , Judge; L.T. Case No. 562011DP145

.

Ana Gomez

- Mallada, Fort Lauderdale, for appellant.

Karla Perkins, Appellate Counsel, Department of Children & Families, Miami, for appellee.

Laura E. Lawson, Sanford, for Guardia n Ad Litem Program.

P ER C URIAM

.

Affirmed

. See In re: S.V.B. , 93 So. 3d 340 (Fla. 2d DCA 2012).

G ROSS

, G ERBER and C ONNER

, JJ., concur.

* * *

Not final until disposition of timely filed motion for rehearing.